Do analysts rate PRTC or SLN?

PureTech Health currently has a consensus price target of GBX 508, suggesting a potential upside of 326.61%. Given PureTech Health's stronger consensus rating and higher possible upside, research analysts clearly believe PureTech Health is more favorable than Silence Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate PRTC or HZD?

PureTech Health currently has a consensus price target of GBX 508, suggesting a potential upside of 326.61%. Given PureTech Health's stronger consensus rating and higher possible upside, equities analysts plainly believe PureTech Health is more favorable than Horizon Discovery Group plc (HZD.L). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Horizon Discovery Group plc (HZD.L) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend PRTC or ARIX?

PureTech Health presently has a consensus price target of GBX 508, indicating a potential upside of 326.61%. Given PureTech Health's stronger consensus rating and higher possible upside, equities analysts plainly believe PureTech Health is more favorable than Arix Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Arix Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

PureTech Health (PRTC) Competitors

GBX 119.08 +1.68 (+1.43%)

As of 08/10/2026 12:01 PM Eastern

Compare

PRTC vs. OXB, SLN, AVCT, HZD, and ARIX

Should you buy PureTech Health stock or one of its competitors? PureTech Health's main competitors and comparable companies include Oxford Biomedica (OXB), Silence Therapeutics (SLN), Avacta Group (AVCT), Horizon Discovery Group plc (HZD.L) (HZD), and Arix Bioscience (ARIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does PureTech Health compare to Oxford Biomedica?

PureTech Health (LON:PRTC) and Oxford Biomedica (LON:OXB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

Oxford Biomedica has a net margin of -17.85% compared to PureTech Health's net margin of -2,355.32%. PureTech Health's return on equity of -31.98% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	-2,355.32%	-31.98%	-13.39%
Oxford Biomedica	-17.85%	-48.56%	-12.67%

PureTech Health has a beta of 0.771, suggesting that its share price is 23% less volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

PureTech Health currently has a consensus target price of GBX 508, suggesting a potential upside of 326.61%. Oxford Biomedica has a consensus target price of GBX 621.85, suggesting a potential upside of 29.96%. Given PureTech Health's higher probable upside, equities analysts clearly believe PureTech Health is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oxford Biomedica	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Oxford Biomedica had 2 more articles in the media than PureTech Health. MarketBeat recorded 2 mentions for Oxford Biomedica and 0 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.00 beat Oxford Biomedica's score of -0.23 indicating that PureTech Health is being referred to more favorably in the media.

Company	Overall Sentiment
PureTech Health	Neutral
Oxford Biomedica	Neutral

32.5% of PureTech Health shares are owned by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are owned by institutional investors. 13.4% of PureTech Health shares are owned by insiders. Comparatively, 25.8% of Oxford Biomedica shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

PureTech Health has higher earnings, but lower revenue than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£4.66M	62.21	-£91.86M	-£46.00	N/A
Oxford Biomedica	£168.74M	3.43	-£143.51M	-£26.92	N/A

Summary

Oxford Biomedica beats PureTech Health on 8 of the 15 factors compared between the two stocks.

How does PureTech Health compare to Silence Therapeutics?

PureTech Health (LON:PRTC) and Silence Therapeutics (LON:SLN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Silence Therapeutics has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£4.66M	62.21	-£91.86M	-£46.00	N/A
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A

PureTech Health currently has a consensus price target of GBX 508, suggesting a potential upside of 326.61%. Given PureTech Health's stronger consensus rating and higher possible upside, research analysts clearly believe PureTech Health is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Silence Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, PureTech Health's average media sentiment score of 0.00 equaled Silence Therapeutics'average media sentiment score.

Company	Overall Sentiment
PureTech Health	Neutral
Silence Therapeutics	Neutral

32.5% of PureTech Health shares are owned by institutional investors. 13.4% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Silence Therapeutics has a net margin of 0.00% compared to PureTech Health's net margin of -2,355.32%. Silence Therapeutics' return on equity of 0.00% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	-2,355.32%	-31.98%	-13.39%
Silence Therapeutics	N/A	N/A	N/A

Summary

PureTech Health beats Silence Therapeutics on 7 of the 11 factors compared between the two stocks.

How does PureTech Health compare to Avacta Group?

Avacta Group (LON:AVCT) and PureTech Health (LON:PRTC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

Avacta Group has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, PureTech Health has a beta of 0.771, indicating that its share price is 23% less volatile than the broader market.

In the previous week, Avacta Group had 1 more articles in the media than PureTech Health. MarketBeat recorded 1 mentions for Avacta Group and 0 mentions for PureTech Health. Avacta Group's average media sentiment score of 0.67 beat PureTech Health's score of 0.00 indicating that Avacta Group is being referred to more favorably in the media.

Company	Overall Sentiment
Avacta Group	Positive
PureTech Health	Neutral

Avacta Group currently has a consensus price target of GBX 99, indicating a potential upside of 53.78%. PureTech Health has a consensus price target of GBX 508, indicating a potential upside of 326.61%. Given PureTech Health's higher possible upside, analysts plainly believe PureTech Health is more favorable than Avacta Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

PureTech Health has a net margin of -2,355.32% compared to Avacta Group's net margin of -33,961.06%. PureTech Health's return on equity of -31.98% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avacta Group	-33,961.06%	-2,929.47%	-21.80%
PureTech Health	-2,355.32%	-31.98%	-13.39%

3.1% of Avacta Group shares are owned by institutional investors. Comparatively, 32.5% of PureTech Health shares are owned by institutional investors. 47.7% of Avacta Group shares are owned by insiders. Comparatively, 13.4% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Avacta Group has higher earnings, but lower revenue than PureTech Health. Avacta Group is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avacta Group	£113K	2,669.36	-£30.08M	-£9.66	N/A
PureTech Health	£4.66M	62.21	-£91.86M	-£46.00	N/A

Summary

Avacta Group and PureTech Health tied by winning 7 of the 14 factors compared between the two stocks.

How does PureTech Health compare to Horizon Discovery Group plc (HZD.L)?

PureTech Health (LON:PRTC) and Horizon Discovery Group plc (HZD.L) (LON:HZD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Horizon Discovery Group plc (HZD.L) has a net margin of 0.00% compared to PureTech Health's net margin of -2,355.32%. Horizon Discovery Group plc (HZD.L)'s return on equity of 0.00% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	-2,355.32%	-31.98%	-13.39%
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A

32.5% of PureTech Health shares are held by institutional investors. 13.4% of PureTech Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Horizon Discovery Group plc (HZD.L) has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£4.66M	62.21	-£91.86M	-£46.00	N/A
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A

PureTech Health currently has a consensus price target of GBX 508, suggesting a potential upside of 326.61%. Given PureTech Health's stronger consensus rating and higher possible upside, equities analysts plainly believe PureTech Health is more favorable than Horizon Discovery Group plc (HZD.L).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Horizon Discovery Group plc (HZD.L)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, PureTech Health's average media sentiment score of 0.00 equaled Horizon Discovery Group plc (HZD.L)'saverage media sentiment score.

Company	Overall Sentiment
PureTech Health	Neutral
Horizon Discovery Group plc (HZD.L)	Neutral

Summary

PureTech Health beats Horizon Discovery Group plc (HZD.L) on 6 of the 11 factors compared between the two stocks.

How does PureTech Health compare to Arix Bioscience?

PureTech Health (LON:PRTC) and Arix Bioscience (LON:ARIX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

In the previous week, PureTech Health's average media sentiment score of 0.00 equaled Arix Bioscience'saverage media sentiment score.

Company	Overall Sentiment
PureTech Health	Neutral
Arix Bioscience	Neutral

Arix Bioscience has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£4.66M	62.21	-£91.86M	-£46.00	N/A
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A

PureTech Health has a beta of 0.771, suggesting that its share price is 23% less volatile than the broader market. Comparatively, Arix Bioscience has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

PureTech Health presently has a consensus price target of GBX 508, indicating a potential upside of 326.61%. Given PureTech Health's stronger consensus rating and higher possible upside, equities analysts plainly believe PureTech Health is more favorable than Arix Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Arix Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Arix Bioscience has a net margin of 105.64% compared to PureTech Health's net margin of -2,355.32%. Arix Bioscience's return on equity of 6.41% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	-2,355.32%	-31.98%	-13.39%
Arix Bioscience	105.64%	6.41%	2.18%

32.5% of PureTech Health shares are owned by institutional investors. Comparatively, 41.3% of Arix Bioscience shares are owned by institutional investors. 13.4% of PureTech Health shares are owned by company insiders. Comparatively, 20.7% of Arix Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Arix Bioscience beats PureTech Health on 10 of the 13 factors compared between the two stocks.

Get PureTech Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRTC vs. The Competition

Export

Metric	PureTech Health	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£285.77M	£3.70B	£7.02B	£2.89B
Dividend Yield	N/A	3.76%	2.58%	6.09%
P/E Ratio	-2.59	9.09	269.20	368.29
Price / Sales	62.21	1,255.34	588.81	83,647.94
Price / Cash	2.14	44.95	28.89	27.89
Price / Book	1.05	17.66	11.27	7.22
Net Income	-£91.86M	-£13.25M	£3.45B	£5.89B
7 Day Performance	0.81%	3.11%	1.92%	1.29%
1 Month Performance	-1.51%	-1.68%	-0.58%	2.22%
1 Year Performance	-8.12%	61.75%	75.49%	73.69%

PureTech Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRTC PureTech Health	2.3339 of 5 stars	GBX 119.08 +1.4%	GBX 508 +326.6%	-10.6%	£285.77M	£4.66M	N/A	300
OXB Oxford Biomedica	2.351 of 5 stars	GBX 505 -14.6%	GBX 669.85 +32.6%	+8.6%	£611.24M	£168.74M	N/A	891	Analyst Forecast High Trading Volume
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	£480.35M	£11.35M	N/A	100	High Trading Volume
AVCT Avacta Group	2.656 of 5 stars	GBX 66.75 -1.1%	GBX 99 +48.3%	+41.7%	£316.27M	£113K	N/A	120
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:PRTC) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PureTech Health (PRTC) Competitors

PRTC vs. OXB, SLN, AVCT, HZD, and ARIX

How does PureTech Health compare to Oxford Biomedica?

Summary

How does PureTech Health compare to Silence Therapeutics?

Summary

How does PureTech Health compare to Avacta Group?

Summary

How does PureTech Health compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does PureTech Health compare to Arix Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PureTech Health (PRTC) Competitors

PRTC vs. OXB, SLN, AVCT, HZD, and ARIX

How does PureTech Health compare to Oxford Biomedica?

Is PRTC or OXB more profitable?

Which has more risk and volatility, PRTC or OXB?

Do analysts recommend PRTC or OXB?

Does the media prefer PRTC or OXB?

Do insiders and institutionals have more ownership in PRTC or OXB?

Which has higher earnings and valuation, PRTC or OXB?

Summary

How does PureTech Health compare to Silence Therapeutics?

Which has stronger valuation and earnings, PRTC or SLN?

Do analysts rate PRTC or SLN?

Does the media favor PRTC or SLN?

Do insiders & institutionals believe in PRTC or SLN?

Is PRTC or SLN more profitable?

Summary

How does PureTech Health compare to Avacta Group?

Which has more risk & volatility, AVCT or PRTC?

Does the media refer more to AVCT or PRTC?

Do analysts recommend AVCT or PRTC?

Is AVCT or PRTC more profitable?

Do institutionals & insiders have more ownership in AVCT or PRTC?

Which has better earnings and valuation, AVCT or PRTC?

Summary

How does PureTech Health compare to Horizon Discovery Group plc (HZD.L)?

Is PRTC or HZD more profitable?

Do insiders and institutionals hold more shares of PRTC or HZD?

Which has stronger valuation and earnings, PRTC or HZD?

Do analysts rate PRTC or HZD?

Does the media prefer PRTC or HZD?

Summary

How does PureTech Health compare to Arix Bioscience?

Does the media refer more to PRTC or ARIX?

Which has stronger earnings and valuation, PRTC or ARIX?

Which has more risk & volatility, PRTC or ARIX?

Do analysts recommend PRTC or ARIX?

Is PRTC or ARIX more profitable?

Do institutionals & insiders have more ownership in PRTC or ARIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools